Trehalose-based coacervates for local bioactive protein delivery to the central nervous system

*Laboni F Hassan, Riya Sen, and Timothy M O'Shea**

Department of Biomedical Engineering, Boston University, Boston, MA, 02215-2407, USA.

* Corresponding author

Summary: Therapeutic outcomes of local biomolecule delivery to the central nervous system (CNS) using bulk biomaterials are limited by inadequate drug loading, neuropil disruption, and severe foreign body responses. Effective CNS delivery requires addressing these issues and developing well-tolerated, highly-loaded carriers that are dispersible within local neural parenchyma. Here, we synthesized biodegradable trehalose-based polyelectrolyte oligomers using facile A2:B3:AR thiol-ene Michael addition reactions that form complex coacervates upon mixing of oppositely charged oligomers. Coacervates permit high concentration loading and controlled release of bioactive growth factors, enzymes, and antibodies, with modular formulation parameters that confer tunable release kinetics. Coacervates are cytocompatible and readily bind to cultured neural cells *in vitro* but remain extracellularly. Coacervates serve as effective vehicles for precisely delivering biomolecules, including bioactive neurotrophins, to the mouse striatum following intraparenchymal injection. These results support the use of trehalose-based coacervates as part of therapeutic protein delivery strategies for CNS disorders.

Keywords: Coacervates; trehalose; protein delivery; neurotrophins; central nervous system; thiol-ene Michael addition; biomaterials; drug delivery; polyelectrolytes.

Introduction

Local delivery of bioactive proteins has been and continues to be explored as part of experimental treatments for various central nervous system (CNS) disorders[1,2]. In CNS injuries such as spinal cord injury (SCI) and ischemic stroke, local delivery of neurotrophins such as Nerve growth factor (NGF), Glial cell line-derived neurotrophic factor (GDNF), Brain-derived neurotrophic factor (BDNF), and Ciliary neurotrophic factor (CNTF) have been used to chemoattract regrowing axons across large complete lesions, guide connectivity of regrowing circuits, or recruit newly proliferated glia and neuroblasts to repair sites of tissue damage[3-10]. In models of neurodegeneration such as Parkinson's and Alzheimer's disease, local delivery of neurotrophins has helped arrest disease progression by improving neuron survival and preserving neural circuit function[11,12], leading to their investigation in clinical trials[13]. To aid neuroplasticity after CNS injury, local delivery of other protein therapies such as extracellular matrix-modifying enzymes has been studied to augment relay circuit formation[14,15]. Ultimately, as our understanding of the pathophysiology of CNS disorders continues to evolve, new protein-based therapeutic candidates will continue to be identified.

Despite their promise, clinical translation of protein-based therapies continues to be hampered by molecular delivery challenges that require new bioengineering solutions. Protein-based therapies do not readily cross the blood brain barrier, so obtaining therapeutic levels in the CNS requires high systemic doses that can be toxic[16] or have substantial off-target effects[17]. While local delivery of proteins to the CNS via high dose bolus intraparenchymal injections or indwelling catheter systems may overcome systemic toxicity issues, a lack of control over concentration and spatial distribution of delivered protein can cause local neurotoxicity[18,19]. Additionally, rapid protein aggregation and proteolytic degradation can limit temporal stability *in vivo*[20]. Injectable or implantable biomaterial-based drug delivery systems can improve upon the spatiotemporal control of protein release to optimize therapeutic effects while minimizing off-target neurotoxicity[21].

Using biomaterials to deliver protein therapeutics has led to improved outcomes in preclinical models of stroke[9,22], SCI[3,4], and Parkinson's disease[23]. However, the fragile nature of these protein-based therapies means that they are particularly susceptible to denaturation during encapsulation into biomaterials as well as during prolonged delivery from biomaterials *in vivo*. Practically, this means that most protein delivered from biomaterials has limited bioactivity beyond the first few days. Foreign body responses (FBRs) that are provoked by bulk biomaterial carriers when introduced into the CNS can also dramatically alter delivery outcomes[24]. Biomaterials that evoke a severe FBR in the CNS cause infiltration of macrophages and microglia and formation of a non-neural cell compartment, thus mediating preferential delivery to these cells rather than to neurons, and in practice, has resulted in reduced neurotrophin efficacy after stroke[24]. Additionally, since the CNS is a constrained anatomical site, implantation of bulk biomaterial carriers, even those amenable to minimally invasive injection, can displace considerable volumes of neural tissue causing CNS damage and dysfunction[24]. If the therapeutic potential of local protein delivery for CNS disorders is to be realized, new strategies are needed to: 1) improve loading and long-term stability of proteins within biomaterials, and 2) minimize the neural tissue disruption caused by biomaterials.

To improve the long-term stability and bioactive delivery of proteins, we and others have incorporated multivalent presentation of trehalose into polymers and hydrogels[25-28]. Trehalose is a non-reducing disaccharide that is produced by yeast and other extremophile organisms to effectively stabilize intracellular proteins, nucleic acids, and cell membranes under extreme environments[29]. The unique strength, spatial orientation, and symmetry of hydrogen bonding afforded by trehalose confers enhanced protein stabilization compared to other excipients[30]. Trehalose has been applied as a cryo-preservative agent in commercial production of cell-based therapies[31] and is included on the "generally regard as safe" (GRAS) list by the FDA. While we have recently incorporated trehalose into poly(trehalose-co-guanosine) glycopolymer hydrogels to alter the natural responses of glial cells after CNS injury[32], trehalose-based biomaterials have yet to be tested as part of local protein delivery systems applied to the CNS.

Given that bulk biomaterials such as hydrogels and scaffolds displace significant volumes of neural tissue upon implantation, different approaches are needed to develop a delivery system that ensures high protein loading capacity and retains protein bioactivity while also being capable of local dispersion into volumes of neural tissue. While polymer nanoparticles can be used to deliver protein therapies[33] and may be readily dispersible in neural tissue[34], it is challenging to prepare nanoparticles with sufficiently high protein concentrations needed for therapy, and formulation methods using harsh organic solvents can denature particularly fragile proteins[35,36]. In this work, we developed and tested an alternative method for dispersible protein delivery to CNS tissue by using a new trehalose-based complex coacervate system. Complex coacervates are small liquid droplets formed as a result of liquid–liquid phase separation evoked by ionic complexation of polyelectrolytes[37]. These self-assembled structures can form homogeneous spherical droplets on the nanometer to micron scale[38], permit very high protein encapsulation[39-41], and may stabilize proteins directly, leading to enhanced bioactivity[42,43]. These properties make complex coacervates excellent candidates for local CNS drug delivery applications.

Here, we hypothesized that multivalent trehalose-based complex coacervates: (i) could be used to load and stabilize high concentrations of proteins; (ii) would be readily dispersible within CNS tissue by non-invasive intraparenchymal injection, causing minimal disruption to healthy neural tissue; and (iii) would evoke a minimal FBR such that proteins can be delivered predominately to neurons and glia rather than to recruited peripherally derived immune cells. To test these hypotheses, we synthesized branched polyelectrolyte trehalose-based oligomers by thiol-ene Michael addition, investigated the formulation conditions needed to prepare stable coacervates, evaluated protein encapsulation and bioactivity stabilization capacity of coacervates *in vitro,* and tested coacervate-based delivery of reporter molecules and bioactive neurotrophins in the healthy mouse striatum. Our findings demonstrate the feasibility of using trehalose-based coacervates for enhanced local protein delivery to the CNS.

Results

Multifunctional anionic and cationic trehalose-based branched oligomers can be synthesized by Thiol-ene Michael addition

Multivalent presentation of trehalose within covalently crosslinked hydrogels effectively stabilizes biomacromolecules during controlled release[27]. Here, we sought to repurpose similar chemistry to generate complex coacervates to enable bioactive protein delivery to volumes of neural tissue with minimal tissue disruption that is otherwise associated with injection of bulk biomaterials[24]. In our previous trehalose-based hydrogel work, we synthesized trehalose diacrylate through regiospecific acylation of 6 or 6′ primary hydroxyl sites by vinyl acrylate in acetone using Candida antarctica Lipase B (CALB)-immobilized on acrylic resin as an enzymatic catalyst[27]. This reaction achieves diacrylate functionalization of trehalose in a single reaction without requiring protection/deprotection steps. However, vinyl acrylate is expensive and is currently difficult to source. We refined the trehalose diacrylate synthesis methodology to increase reaction yields and improve affordability by making the following adjustments: i) substituting vinyl acrylate with 2,2,2-Trifluoroethyl acrylate (TFEA) (TFEA is ~7% the cost of vinyl acrylate per gram); ii) using anhydrous trehalose instead of trehalose dihydrate; and iii) using 2-methyl-2-butanol (2M2B) instead of acetone as a reaction solvent (Figure 1A). Whereas transesterification with vinyl acrylate affords an unstable enol leaving group upon acylation of trehalose, effectively making the reaction irreversible[44], the use of TFEA introduces the possibility of the reverse competing hydrolysis reaction taking place during trehalose acylation. However, with TFEA, the three electron withdrawing fluorine groups reduce the nucleophilicity of the 2,2,2-trifluoroethanol leaving group such that we readily derived the trehalose diacrylate product (Figure 1A, S1)[45]. Solubilizing anhydrous trehalose in DMSO before combining with 2M2B also increased solubility of trehalose in the organic media and improved the overall yield of trehalose diacrylate. As before, trehalose diacrylate was readily purified by silica flash chromatography to yield the pure product (Figure 1A, S1) and required the addition of 4-methoxyphenol (MEHQ) to prevent free-radical homopolymerization during work-up[27].

Next, we synthesized trehalose-based branched oligomers using an A2+B3+AR reaction scheme[46] involving base-catalyzed thiol-ene Michael addition step-growth between trehalose diacrylate (A2), trimethylolpropane tris(3-mercaptopropionate) (TMPTMP) (B3), and various charged monoacrylate end-capping species (AR) (Figure 1B). We investigated 4 different end-cap species: i) 2-carboxyethyl acrylate (C), and ii) 2-(dimethylamino) ethyl acrylate (D) which are ionizable monomers with functional groups that have pKa values within two to three units of physiological pH making them partially charged species under such conditions; as well as iii) 3-sulfopropyl acrylate (S) and iv) 2-acryloxyethyl trimethyl ammonium chloride (A) which are constitutively charged monomers (Figure 1B). Branched oligomers functionalized with C or S end-caps are polyanions while D or A end-cap functionalization generates polycation oligomers. Nomenclature for oligomers followed the following convention: “b” for branched; "C", “D”, “S”, or “A”, to denote end-cap functionality; and a numerical value corresponding to the intended branching functionality (f_b) of the synthesis (Figure S2). Branched oligomer synthesis was performed in one-pot at a concentration of 100 mg/ml in a DMF/water mixed solvent with N,N-Diisopropylethylamine (DIEA) as a catalytic base to initiate the reaction (Figure 1B). Combining end-capping monoacrylates (AR) at the onset of the reaction effectively avoids crosslinking and gelation of A2+B3 systems at high conversion[47]. Irrespective of the end-cap species used, oligomer reactions proceeded with complete consumption of thiol and acrylate groups, as monitored by TLC developed with Ellman’s and CAM reagents (Figure 1C) as well as by NMR (Figure 1D, S3). We first prepared oligomers with each end-cap at a fixed stoichiometric ratio of 0.5:1:2 (A2:B3:AR) for a f_b of 1.71. Adjusting the reaction stoichiometry to 1:1:1 and 1.375:1:0.25 (A2:B3:AR), to increase the f_b to 2.00 and 2.29 respectively, was associated with increased trehalose content and a reduction in the proportion of end-caps on the oligomer as measured by FTIR and NMR (Figure 1E, S4). Number average molecular weights (Mn) for oligomers estimated by NMR ranged from approximately 2 kDa for f_b of 1.71 to 15 kDa for f_b of 2.29 with the oligomer molecular weights altered minimally by the different end-cap species (Figure S5). The f_b of 2.29 was determined to be the upper limit of oligomer branching permitted without inducing insoluble crosslinked net-

works, but significant intramolecular cyclization likely still occurs at this functionalization[46]. Consistent with chemical characterization of branching properties, constitutively charged oligomers with A or S end-caps had positive and negative zeta potentials respectively that were directly proportional to the stoichiometrically controlled density of end-cap species on the oligomer (Figure 1F). To purify oligomers, reaction solutions were concentrated *in vacuo* and acidified or alkalized in aqueous solutions depending on the end-cap to dissolve the oligomer in the aqueous phase, followed by liquid-liquid extraction with ethyl acetate to remove DIEA, DMF, and any low molecular weight or minimally end-capped oligomers. Yield after purification and lyophilization was typically 50-60%. These data show that branched trehalose oligomers of different charges could be readily synthesized at high scale using A2+B3+AR thiol-ene Michael addition.

Aqueous solubility of trehalose-based branched oligomers is altered by salt and pH

Complex coacervates are formed through liquid–liquid phase separation caused by association of two oppositely charged polyelectrolytes[48]. Formation of coacervates is conditional on each polyelectrolyte maintaining aqueous solubility prior to mixing, but polyelectrolyte solubility can be dramatically altered by salt and pH conditions. Therefore, we next evaluated how salt concentration and pH of aqueous buffers affected the solubility of trehalose-based branched oligomers with different f_b and end-cap functionalization. All oligomers with f_b ranging from 1.71-2.29 irrespective of end-cap functionalization could be readily dissolved in unbuffered water at 500 mg/ml. To test salt effects on solubility of ionizable versus constitutively charged oligomers, we screened differently branched oligomers with either A or D cationic end-caps under NaCl concentrations ranging from 0-500 mM. Solubility was screened using spectrophotometric turbidity measurements with absorbance values greater than 0.5 units defined as insoluble (Figure 2A). At 10 mg/ml, highly branched (f_b = 2.29) oligomers were insoluble after addition of only a small amount of salt, indicating that oligomers with minimal charged end-caps, high branching, and possible intramolecular cyclization were readily affected by salt screening. Oligomers with f_b = 1.71 remained soluble up to salt concentrations of 500 mM with no differences detected between the two different cationic end-caps. All

oligomers with f_b = 2.00 were soluble up to physiological salt concentrations (~150 mM) irrespective of chemical composition of the end-cap (Figure 2D).

For pH experiments, isotonic pH adjustable buffers were used to derive solutions with pH buffering capacity ranging from 4.5-8.5. Polycationic and polyanionic oligomers with f_b up to 2.00 were solubilized in water at 500 mg/ml and diluted into different pH buffers at a final concentration of 10 mg/ml. Oligomers with constitutively charged A and S end-caps displayed no pH dependent solubility changes as expected (Figure S6). D end-capped oligomers with f_b = 2.00 (bD2.00) were fully soluble under mildly acidic conditions (pH <6.5) where the end-cap tertiary amines are essentially fully protonated (Figure 2B). bD2.00 displayed an apparent pKa of 7.99 in aqueous buffers, and at pH values greater than this apparent pKa, the oligomer started to become insoluble (Figure 2B, S7). With lower f_b, bD1.71 readily maintained solubility across the tested pH range, and was attributed to a higher net charge due to more end-cap species on the oligomer, rather than an alteration to the effective pKa. bC2.00 was soluble under physiologic pH and mildly basic conditions, but this oligomer formed insoluble precipitates under acidic (pH<5) conditions (Figure 2B). Just like for D end-capped oligomers, C end-capped oligomers with lower branching and higher end-cap functionality showed a more extended pH range in which they were soluble (Figure 2B). These data show that branched trehalose-based oligomers require a minimum effective charge by electrolytic dissociation of end-caps for oligomers to maintain aqueous solubility and that charge neutralization can provoke immiscibility of highly branched trehalose-based oligomers. Such charge dependent solubility behaviors are important factors in driving phase separation and coacervation versus soluble complex formation upon interaction of oppositely charged polyelectrolytes.

Trehalose-based coacervates form by mixing oppositely charged oligomers

Next, we screened for complex coacervate formation by mixing different combinations of oligomers with f_b = 2.00 in isotonic phosphate buffered saline at pH = 6.0. Oligomer f_b was chosen to maximize trehalose content on the oligomers to confer the greatest potential protein stabilizing effect in resulting coacervates while maintaining

solubility in isotonic conditions and minimizing intramolecular cyclization (Figure S5) that occurs with highly branched oligomers. Buffer conditions were selected based on prior salt and pH solubility results to optimize charge density for bC and bD oligomers before mixing. As before, all individual oligomers were soluble as determined by spectrophotometric turbidity measurements (Figure 2C,D). Combining two different oligomers of the same charge type, namely bD2.00+bA2.00 or bC2.00+bS2.00, at a 1:1 molar ratio did not evoke phase separation or coacervation (Figure 2D,F). However, upon mixing any two oppositely charged oligomers under the same conditions, we observed rapid liquid-liquid phase separation that resulted in significantly increased turbidity and formation of coacervate droplets with sizes ranging from 5-50 μm (Figure 2D,E). While all 4 combinations of oppositely charged oligomers (bC2.00+bD2.00, bC2.00+bA2.00, bS2.00+bD2.00, bS2.00+bA2.00) formed coacervates with equivalent relative turbidity, there were some detectable variations in the size distribution and shape of the coacervates immediately after mixing (Figure 2E). Irrespective of these minor initial variations, all coacervate formulated at this concentration (10 mg/ml) coalesced into a bulk liquid phase within 30 minutes (Figure 2C). Based on these data and the understanding that the ionizable carboxylate and tertiary amine chemical functionalities are likely to be better tolerated *in vitro* and *in vivo*[49,50], we opted to explore coacervates derived from oligomers end-capped with C and D functionality for the remainder of the studies reported here.

To map the formulation space and better understand factors that alter complex coacervate derivation using trehalose-based branched oligomers, we evaluated the effect of modifying oligomer concentration, charge ratio, salt concentration, and pH buffering conditions (Figure 3). At a 1:1 molar ratio of bC2.00 and bD2.00, a minimum concentration of 1 mg/ml of total oligomer was required to generate microscopically detectable coacervates, with the size of initially formed coacervate droplets increasing with higher oligomer concentrations up to 25 mg/ml (Figure 3A,B). Coacervate formation was minimally impacted by minor perturbations in the molar ratio of bC2.00 to bD2.00 on either side of 1:1 stoichiometric equivalency at a fixed total oligomer concentration of 10

mg/ml. With increasing divergence from stoichiometric equivalency, resultant coacervate sizes decreased by approximately 10-fold. At very high charge imbalances (e.g. > 16:1), coacervates did not form and a clear solution persisted upon mixing (Figure 3C,D). There was a significant effect of solution salt concentration on coacervate size with a near two-fold decrease in overall coacervate diameter being detected as buffer salt concentration was increased from 0 to 500 mM (Figure 3E,F). There was minimal effect of pH on resultant coacervates formulated within a pH range of 6 to 8 (Figure 3G,H). Coacervates formulated at high concentrations (>5 mg/ml) in PBS resulted in coalescence of small spherical droplets into a bulk contiguous liquid coacervate phase (Figure 3I). This bulk liquid coacervate phase could be readily resuspended and dispersed into smaller microdroplets of less than 20 μm in diameter by simply diluting with PBS (Figure 3I). Dilute coacervate solutions (<1 mg/ml) that did not display microscopic sized coacervates formed stable nanodroplets that were detectable only by dynamic light scattering (DLS), with coacervate size decreasing proportionally with coacervate concentration from >1000 nm at 1 mg/ml to less than 500 nm at 0.0625 mg/ml (Figure 3J).

These data show that trehalose-based oligomers form complex coacervates that coalesce into a bulk liquid phase upon mixing of oppositely charged oligomers and that coacervate formation occurs over a wide range of experimental conditions including under physiological salt and pH conditions. Although concentrated coacervates form bulk liquid phases quickly, this bulk phase can be readily dispersed into stable micro- and nano- droplets through simple mixing and dilution in biologically relevant buffers.

Trehalose-based coacervates can be loaded with high concentrations of protein

To begin investigating protein incorporation into trehalose-based coacervates, we employed a readily available model protein, lysozyme (Lyz), to conduct initial studies. The size of Lyz (~15 kDa) and its positive charge under physiologically buffered conditions (isoelectric point (pI) = 10-11) is similar to many neurotrophins, making it an appropriate surrogate for neurotrophins in our initial evaluations. In PBS, FITC conjugated Lyz (FITC-Lyz) was combined with bC2.00 and bD2.00 oligomer solutions at varied loading

ratios (LR, oligomer mass/protein mass (mg/mg)) ranging from 25 to 100, with total protein concentration kept constant at 1 mg/ml. To enhance the protein loading potential of the positively charged FITC-Lyz, it was first combined with the soluble polyanion, bC2.00, prior to mixing with bD2.00. FITC-Lyz readily incorporated into coacervates irrespective of LR with rapid coacervate formation observable by time-lapse fluorescence microscopy captured over 15 seconds. Coacervate size at time of mixing was directly proportional to the LR, likely due to a paralleled increase in total oligomer concentration, such that coacervates with an average radius of 3.5 μm were detected with a LR of 25 while 20.3 μm radius coacervates were generated with a LR of 100 (Figure 4A,B). Coacervates formulated with protein at the lower LR of 25 persisted as stable micron-sized coacervates for several hours, whereas the higher LR samples coalesced into a bulk liquid phase quickly, within minutes. To quantify protein encapsulation efficiency, the coacervate liquid phase was isolated from the solution by centrifugation and the depletion of protein from the solution was characterized by fluorometry. Concentrating factor, which was defined as the fold-increase in detected concentration of the protein in the coacervate phase relative to its solution starting concentration, was computed by accounting for the total volume of coacervate formed and the total protein encapsulated. Increasing the oligomer solution concentration at a fixed LR (Figure 4C) or increasing the LR at a fixed protein solution concentration (Figure 4D) both served to increase the encapsulation efficiency of FITC-Lyz. At a fixed LR of 10, encapsulation efficiency as a function of oligomer solution concentration (1-100 mg/ml) followed a one phase association relationship with a plateau encapsulation of approximately 91% (Figure 4C). By contrast, the concentrating factor parameter showed a local maximum value of 14 at a much lower 20 mg/ml oligomer concentration. At a fixed protein solution concentration of 3.6 mg/ml, LR of 35 or more achieved a plateaued encapsulation efficiency of 93-99.6%. At this fixed protein solution concentration, the concentrating factor peaked at a LR of 10, resulting in formation of a coacervate phase loaded with FITC-Lyz at nearly 69 mg/ml (Figure 4D). To evaluate how robustly different proteins could be loaded into coacervates, we assessed encapsulation efficiencies and concentrating factors for other model proteins including FITC-labeled Bovine Serum Albumin (FITC-BSA) (pI = 4.5-5.0), FITC-labeled Human IgG (pI = 6.5-9.5), and unlabeled recombinant human neurotrophin,

NGF (pI = 9.5) in PBS. Coacervate encapsulation efficiencies for these proteins were dependent on overall net protein charge in the formulation buffer (pH = 7.4 for NGF and IgG, pH = 6.5 for FITC-BSA), such that the least charged protein under these conditions, IgG, had the lowest encapsulation efficiency at 54% whereas the most charged protein, Lyz, was nearly completely partitioned into the coacervate phase with an encapsulation efficiency of >99% (Figure 4E). Irrespective of the protein used, coacervate formation resulted in a concentrating effect of at least 2.6-fold (Figure 4E).

We next explored how perturbing the molar ratio of polyanionic and polycationic oligomers altered protein encapsulation efficiency. To detect the relative contributions of molar ratio differences on protein encapsulation, we conducted studies using relatively dilute oligomer solutions (10 mg/ml) and a low LR of 10 which collectively promotes only a moderate encapsulation efficiency of ~15-20% for both FITC-Lyz and FITC-BSA at stoichiometric equivalent ratios of the two oppositely charged bC2.00 and bD2.00 oligomers (Figure 4F,G). Formulations with excess polyanion, bC2.00, enhanced the relative encapsulation efficiency of cationic FITC-Lyz by approximately 4-fold, suggesting that charge imbalance can be an effective way to sequester more oppositely charged protein from the solution. However, for FITC-Lyz there was no significant increase in encapsulation detected beyond a molar ratio of imbalance 2:1 (C:D) (Figure 4F). Formulations prepared with excess polycationic bD2.00 oligomers did not result in a depletion of loaded FITC-Lyz compared to stoichiometric equivalency, suggesting an excess of like charges does not repel protein from the coacervate. For FITC-BSA, which has an acidic pI, preparing coacervates with an excess of polycationic oligomers also showed increased protein encapsulation (Figure 4G). However, in this instance, increasing the molar ratio imbalance up to 1:8 C:D did further increase the encapsulation of FITC-BSA compared to 1:2 C:D such that over 85% protein was partitioned into the coacervate phase. Interestingly, formulating FITC-BSA with just the polycationic bD2.00 oligomer alone was sufficient to induce coacervate formation, resulting in 87% FITC-BSA encapsulation. By contrast, bC2.00 alone with FITC-Lyz provoked formation of a minimal coacervate phase and a limited depletion of protein from the solution. These dissimilar

outcomes can be readily attributed to differences in the immiscibility of the two oligomers in their neutralized states. Despite the significant contribution of oligomer charge imbalance in dilute solutions, at a higher LR of 50, the encapsulation efficiency was only minimally altered by perturbations in the molar ratio with all formulations having over 80% encapsulation efficiency at this LR and all but one formulation enabling 94-99.6% encapsulation (Figure 4H).

These data show that trehalose-based coacervates permit high encapsulation efficiency and concentration loading of a variety of different proteins including growth factors, enzymes, and antibodies. Encapsulation efficiency and concentrating factor for proteins loaded into coacervates can be readily tuned on a protein-by-protein basis by optimizing formulation parameters such as the LR, oligomer and protein solution concentration, and molar imbalance of oppositely charged oligomers.

Trehalose-based coacervates show temporally controlled bioactive protein release

We hypothesized that protein released from bulk coacervates could involve a combined contribution from several possible mechanisms including release via: (i) Fickian (first order) diffusion; (ii) oligomer ester degradation; (iii) bulk coacervate loss occurring through coacervate disassembly; or (iv) coacervate surface erosion leading to a steady surface blebbing of small coacervate droplets from the coacervate bulk. To determine the relative contributions of these potential mechanisms to overall protein release we started by investigating how coacervates degrade in the absence of loaded protein cargo. By selectively incorporating a small proportion of fluorescein labeling on bC2.00 using a fluorescein o-acrylate end-cap, we monitored mass of bulk coacervate material lost following daily replenishment of PBS supernatant. The rate of mass loss was maintained at essentially a constant rate (2-4 mg/day) across samples of increasing total mass such that 10 mg of coacervate sample was totally depleted within 4 days while 40 mg of sample took 10 days to completely resorb (Figure 5A). The approximate zero-order kinetics of coacervate mass loss suggested that surface erosion, rather than disassembly of charge interactions or ester hydrolysis, was the predominant mechanism

of coacervate loss. Analysis of coacervate supernatants by DLS revealed the presence of nano- and micro- sized droplets in supernatants after each day of release, with >1 μm sized droplets on the first day of the incubation period followed by consistently sized droplets in the range of 250-650 nm detected thereafter (Figure 5B). Chemical analysis of the recovered coacervate supernatants by FTIR did not detect any emergent carboxylate groups in the C=O stretch at 1550-1610 cm^{-1} that would otherwise be present if there was substantial hydrolysis (Figure 5C). These data are consistent with the notion that coacervates are blebbing off from the coacervate bulk and diffusing into the supernatant as micro- and nano-sized droplets, suggesting that there is no disassembly of coacervate charge interactions and negligible oligomer hydrolysis up to at least 10 days of aqueous incubation.

To evaluate protein release from coacervates we first incorporated FITC-Lyz into coacervates at different LRs with a fixed protein mass of 0.7 mg and C:D ratio of 1:1, such that there was essentially equivalent protein encapsulation across the different samples (93-99%) and evaluated protein release from bulk coacervates into PBS that was replaced daily. There was reduced initial burst and decreased total FITC-Lyz released from coacervates with increasing LR (Figure 5D). Surprisingly, the total amount of FITC-Lyz recovered from surface eroding coacervates was low across all samples. Approximately 20% of total FITC-Lyz was recovered from coacervates with a LR of 25 while we detected essentially no released FITC-Lyz for up to 5 days in coacervates with a LR of 100 and in this formulation only around 5% of total loaded FITC-Lyz was recovered (Figure 5D). For a fixed LR, mixing FITC-Lyz with the polyanion prior to coacervate formulation with the polycation provided a small but significant increase in encapsulation efficiency when compared to protein loading after coacervate formation but did not alter the overall percentage of protein recovered during *in vitro* release (Figure S8). Associated with the decreasing recovery of FITC-Lyz in coacervates with higher LR was the presence of water-insoluble precipitates in the supernatant that only emerged after the first 5 days of incubation when most of the coacervate bulk had eroded away (Figure S9). There was negligible additional release of FITC-Lyz from the solid precipitates for the 12 days of testing indicating that these precipitates were likely particularly stable

solid protein-oligomer complexes (Figure 5D). From these results we inferred the coexistence of both liquid coacervate and solid precipitate phases when trehalose-based oligomers are formulated with Lyz, with the relative abundance of protein within the precipitate phase increasing with a greater excess of oligomer. Prior studies have demonstrated a preference towards solid precipitate formation when Lyz is combined with polyanions due to its particularly high isoelectric point and density of cationic charge at physiologic pH[51]. To confirm that the formation of solid precipitates with Lyz is due directly to polyanion interactions, we examined formulations with an increasing excess of polyanion species at a constant LR of 50 (Figure 5E). Although the extent of protein release during the first 5 days of coacervate erosion was essentially unchanged, a higher ratio of polyanion oligomers resulted in greater retention of FITC-Lyz in the precipitate phase, consistent with literature[51](Figure 5E). We also detected co-existence of coacervate and precipitate phases in FITC-BSA formulations with the same LR. However, there was minimal effect of excess polycation on FITC-BSA recovery and there was continuous release of FITC-BSA from the precipitate phase during a 24-day testing period (Figure 5F). These data are consistent with FITC-BSA-oligomer solid precipitates being less stable compared to those formed with FITC-Lyz, owing to the lower density of charge on BSA at physiological pH. It was also notable that fluorescein-labeled coacervates formulated with either unlabeled Lyz or unlabeled BSA showed faster coacervate surface erosion compared to empty fluorescein-labeled coacervates, suggesting that the solid precipitate formation disrupts the stability of coalesced coacervates (Figure S10). Overall, these protein release data suggest that trehalose-based oligomers effectively prolong protein release via combined action of coacervate surface erosion followed by solid precipitate dissolution and that the net release profile is both protein and formulation dependent.

Intraparenchymal infusions of macromolecules or nanoparticles into the CNS results in extensive transport of these entities along perivascular spaces of blood vessels throughout neural tissue via convection-enhanced delivery (CED) that may ultimately hamper desired local therapeutic effects[52,53]. To assess *in vitro* whether coacervates might mitigate the extent of CED and retain molecules within more focal tissue volumes,

we evaluated transport of different molecular weight dextrans and proteins loaded into coacervates following injection into 0.6 wt% agarose gel phantom brains (Figure S11), which serve as effective *in vitro* systems for modeling CED[54]. We loaded non-ionic rhodamine labeled dextran (10 kDa) into fluorescein-labeled coacervates so that we could track both coacervate and dextran transport individually through the phantom (Figure 5G). Non-charged dextrans have minimal electrostatic interactions with oligomers thus mitigating the formation of a precipitate phase. There was notably slower transport of coacervate loaded with dextrans through the agarose phantom compared to the dextran solution over the course of 24 hours, with dextran retention correlating with coacervate retention in the agarose (Figure 5G). The co-dispersion of coacervates and dextrans illustrates that loaded cargo does not readily diffuse out of coacervates, but that coacervates remain as a protective carrier for cargo throughout dispersion through the agarose. Coacervates enhanced the retention of dextrans of various sizes in agarose phantoms over a 2-week period *in vitro* with 76% of 10 kDa and 94% of 150 kDa dextran retained in the agarose by formulating with coacervates. By contrast, no 10 kDa dextran and only 17% of 150 kDa dextran was retained in agarose phantoms at 2 weeks when injected as a solution (Figure 5H, S12). Monitoring recovered FITC-Lyz injected into agarose phantoms also showed enhanced local retention using coacervates with greater than 60% of protein preserved in the agarose phantom after 1 week whereas FITC-Lyz solution was completely removed from the agarose after just 2 days (Figure 5I). Collectively, these data show that coacervates may be an effective way of minimizing CED effects to retain high local concentrations of molecular cargo, including proteins and non-charged polysaccharides, in narrow tissue zones *in vivo*.

To determine the capacity of trehalose-based coacervates to maintain the bioactivity of loaded proteins, we loaded horseradish peroxidase (HRP) into coacervates and monitored time-, temperature-, and lyophilization- dependent effects on enzymatic activity compared to HRP solutions. HRP is a suitable model protein for evaluating the effects of trehalose-based coacervates on protein stability and function since any conformational or structural perturbations to HRP cause loss of enzymatic activity, and dilute solutions of HRP become inactive within 24 hours[27]. Formulating HRP into coacervates

did not alter the bioactivity of the enzyme, and coacervates preserved HRP enzymatic activity for up to 4 days longer at 37°C *in vitro* compared to the HRP solution (Figure 5J). Formulating HRP into coacervates provided moderate protection against denaturing thermal stressors, such that higher preserved enzymatic activity was maintained at 50ºC, although the stabilizing effect was lost at temperatures at or above 60ºC (Figure 5K). Trehalose-based coacervates also enabled lossless recovery of bioactive HRP following lyophilization, which was an improvement on the recovery from protein solution only formulations (Figure S13). These data show that coacervates are effective carriers for maintaining long-term functional bioactivity of proteins during controlled release.

Trehalose-based coacervates are cytocompatible and adhere to neural cells *in vitro*

To test the cytocompatibility of trehalose-based coacervates with neural cells, we exposed proliferating mouse neural progenitor cells (NPC) and quiescent mouse astrocyte cultures to coacervates *in vitro* (Figure 6, S14). Formulated coacervates, as well as their individual constituents, bC2.00 and bD2.00, were tolerated well by both NPC (Figure 6A) and quiescent astrocytes (Figure 6D) at all concentrations tested up to 1 mg/ml with cell viability being not significantly different to that of untreated controls. In a separate assay, the number of viable NPC detected after 24 hours was directly proportional to the treated coacervate concentration with the highest 1 mg/ml concentration promoting a 30% increase in the number of detected NPC compared to the lower 0.03125 mg/ml concentration (Figure S14). Since NPC proliferation rates are exquisitely sensitive to the concentrations of EGF and FGF growth factors used in the cell culture media[55], these data are consistent with coacervates acting to sequester growth factors from the media and presenting higher local concentrations of growth factors to cells (Figure S14). Using fluorescein-labeled coacervates to visualize coacervate-cell interactions, we noted that many of the micro-sized coacervates that form at the 1 mg/ml concentration seemed to readily adhere to both neural cell types after 24 hours of incubation, but there was no obvious internalization or lysosomal trafficking of coacervates into cells (Figure 6C,F). Adhesion of coacervates to cells was a surprising observation since we anticipated that a net neutral, trehalose-based surface would be non-fouling[56]. To

further investigate this, we probed whether a surface layer of bulk coacervates promoted cellular attachment by coating non-treated suspension polystyrene plates with 2 mg/ml of coacervates or constituent oligomers, culturing cells directly on top of the thin residual material layer and evaluating the proportion of adhered cells resistant to wash-off after 24 hours. For NPC, the coacervate layer or adsorbed oligomer surface significantly increased the proportion of attached cells by almost four-fold compared to polystyrene controls with over 90% of cells remaining adhered (Figure 6B). Cultured astrocytes showed a similar capacity to adhere to coacervates and individual oligomers, although polyanionic oligomers showed slightly reduced cell attachment (Figure 6E). Other peptide-based coacervate systems have effectively delivered proteins intracellularly via an endocytic pathway[57,58]. To test whether trehalose-based coacervates were also capable of intracellular protein delivery, we treated astrocytes with coacervates loaded with FITC-BSA. Without a suitable carrier, BSA is not extensively transported into the cell cytoplasm[59] and, since it is well tolerated by *in vitro* cultures, it serves as a suitable model protein to evaluate intracellular delivery. Cultured astrocytes treated with FITC-BSA loaded coacervates for 4 or 24 hours did not increase the intracellular BSA concentration within the cell cytoplasm compared to FITC-BSA solution controls and micro-sized coacervates persisted on the surface of cells throughout the 24-hour period of evaluation (Figure 6G, S15). We suspect that the lack of intracellular delivery or endocytosis of coacervates could be in part the result of direct binding of cell culture media constituents, such as growth factors (NPC) or serum proteins (astrocytes), to the surface of coacervate droplets, but future studies will be required to rigorously dissect this hypothesis. Nonetheless, these data show that trehalose-based coacervates are cytocompatible and readily bind to cells but are not rapidly internalized such that loaded protein cargo is maintained extracellularly.

Trehalose-based coacervates permit local bioactive protein delivery to the mouse striatum

The favorable cytocompatibility and bioactive protein release properties of trehalose-based coacervates motivated us to test coacervate-based delivery *in vivo* in the mouse CNS. Rheological evaluations revealed that bulk coacervates are viscoelastic

but readily thin upon application of high strain (Figure S16A), indicating that we could easily draw up coacervates into narrow glass micropipettes for infusion into the mouse brain (Figure S16B). We injected coacervates into the caudate putamen region of mouse striatum, which is a readily accessible brain region that contains diverse neural parenchymal elements. To evaluate delivery outcomes, we used a standardized CNS FBR immunohistochemistry (IHC)-based framework that we have validated extensively[24,32]. As part of this assay, we loaded biotinylated dextran amine (10 kDa) (BDA), a non-bioactive model macromolecule, into coacervates to track coacervate-dependent CNS molecular delivery outcomes by IHC. We evaluated coacervate-dependent delivery of BDA in two forms: (i) as coacervate bulk (100% v/v phase-separated material), or (ii) as diluted coacervates suspended within a BDA containing solution at 10% v/v phase-separated material. Both bulk and suspended coacervates were formulated at a LR of 100 and 1:1 ratio bC2.00 to bD2.00. To compare coacervate delivery, we employed BDA-only solutions as well as a BDA loaded methyl cellulose (MC)-based hydrogels as benchmarking controls[24,32]. Detailed quantitative IHC analysis on brain tissue sections recovered from cohorts of treated mice revealed notable differences in neural tissue biodistribution between the four different treatments at 7 days after injection (Figure 7A-F). Infused bulk coacervates could be readily detected at 24 hours after injection by BDA staining as micro-sized spherical droplets, with coacervates dispersing throughout a narrow region of neural parenchyma in the striatum that was no more than approximately 380 μm wide with individual coacervates intermingling within beds of NeuN-positive neurons (Figure S17A,C). Bulk coacervate injections caused minimal disruption of neural tissue that is otherwise observed for bulk hydrogel injections into striatum[24,32] (Figure 7B,G,I), with essentially no DAPI-negative regions detected for coacervate-treated brains at 24 hours after injection (Figure S17B). This result is characteristic of tissue dispersal of coacervates rather than deposition of large volumes of material that causes local tissue displacement around the material. Evaluation of infused BDA solution at 7 days after injection revealed extensive uptake of BDA into neurons and axons throughout the striatum and the cortex as well as transport of BDA along large blood vessels resulting in extensive accumulation of BDA in perivascular spaces and at the meninges (Figure 7A,C,D, S18). By contrast, bulk coacervate-based delivery resulted in

reduced tissue penetration of BDA such that the 50th percentile of detected BDA was constrained to within a radial distance of less than 75 μm from the injection epicenter which was 26% of the BDA tissue penetration observed for both the BDA solution and MC hydrogels (Figure 7D). Bulk coacervate treated mice showed no detectable accumulation of BDA along perivascular spaces or at the meninges (Figure S18). Suspended coacervates (10% v/v) increased the striatal penetration of BDA compared to bulk coacervates such that it was no different to BDA solutions, although suspended coacervates had notably less cortical and meningeal delivery compared to BDA solutions (Figure 7C-F, S18). Constrained BDA delivery by bulk coacervates was correlated with significantly less total BDA accumulation in neural tissue compared to BDA solution, but it was equivalent to that detected for MC hydrogels (Figure 7E,F). This decreased BDA accumulation is consistent with a reduction in BDA diffusion and cell uptake throughout the neuropil occurring acutely, which is typical of delayed release systems[24]. BDA released locally from coacervate formulations was taken up by NeuN-positive neurons but was not detected in Iba-1 positive microglia (Figure S19).

Severe FBRs to locally injected biomaterials can result in the formation of non-neural cell compartments due to the localized recruitment and persistence of blood-borne innate immune cells at the biomaterial interface[24]. Neither suspended nor bulk coacervate treatments induced formation of any non-neural compartment and there was minimal peripherally-derived immune cell recruitment, exhibiting no difference in the overall numbers of Ly6b2-positive neutrophils and Cd13-positive myeloid lineage cells (e.g. macrophages, monocytes) for coacervates compared to the solution control at 7 days post-injection (Figure S20A-C). Bulk coacervates evoked an elevated and more diffuse astrocyte reactivity response, measured by increased Gfap expression, compared to either suspended coacervates or solution controls (Figure 7G,H, S21). However, despite the increased astrocyte reactivity response caused by bulk coacervate injections, there was no difference in the overall magnitude of this response compared to MC hydrogels (Figure S22). Notably, coacervates did not provoke the formation of new glial limitans-like borders or cause any significant depletion of NeuN-positive neural tis-

sue which is otherwise associated with MC hydrogel treatment (Figure 7G-I). Bulk coacervates moderately increased expression of vimentin in local astrocytes at the injection site compared to solution-only controls consistent with increased astrocyte reactivity (Figure S23A,B). We did not detect any Ki67-positive astrocytes in coacervate-treated or solution groups at 7 days after injection but there were notably fewer Sox9-positive astrocytes at the injection epicenter of coacervate treated mice (Figure S23C). Bulk coacervate treatment promoted a small but significant localized elevation in Iba-1-positive cells at the injection epicenter which was correlated with a small decrease in the number of P2ry12-positive microglia compared to solution controls (Figure S20D-F). Downregulation of P2ry12 and upregulation of Iba-1 suggests that bulk coacervates cause a small but detectable local activation of microglia at the injection site.

To assess bioactive protein delivery to the CNS using coacervates, we applied a neurotrophin delivery model that we have used previously in the evaluation of hydrogel-based delivery systems[24]. This model leverages the established biological effect of the neurotrophin, NGF, on basal forebrain cholinergic neurons. These neurons are sensitive to extracellular NGF concentrations such that they atrophy when deprived of NGF and hypertrophy when exposed to exogenous NGF. Measurable changes in striatal cholinergic neurons following injections of soluble NGF or delivery of NGF from biomaterials can be readily detected by choline acetyltransferase (ChAT) IHC staining and subsequent analysis of increased number and size of these cells as well as increased density of cholinergic axon networks[24]. The NGF coacervate formulation had a LR of 100 and a slight excess of polyanion bC2.00 (C:D = 1.25:1) and was delivered as a bulk 100% v/v formulation. Coacervates effectively delivered bioactive NGF, causing a significant 78% increase in ChAT intensity and approximately 35% increase in neuron size in the ipsilateral striatum compared to its contralateral side, whereas saline treated controls showed no changes in these parameters (Figure 8A-C, S24). The extent of the NGF-induced changes to ChAT-positive neurons in the ipsilateral striatum promoted by coacervate-based NGF delivery were not significantly different to that evoked by NGF solution (Figure 8B,C). However, coacervate-based delivery resulted in a more focal treatment effect, such that increases in ChAT intensity were isolated to a narrower 700 μm radial

distance from the injection epicenter for coacervates whereas the NGF solution increased ChAT intensity throughout the entire ipsilateral striatum (Figure 8D) as well as in the contralateral striatum (Figure 8E). Cumulative representations of ChAT intensity in the ipsilateral striatum show that coacervates and solution have a similar effect close to the injection but that coacervates begin to have a reduced effect around 500 μm from the injection epicenter (Figure 8F). Cumulative ChAT intensity in the contralateral striatum further illustrates the extensive distribution of NGF solution to the mouse brain whereas coacervates minimize that effect (Figure 8G). These data show that trehalose-based coacervates are effective vehicles for precisely delivering bioactive proteins to the neuropil.

Discussion

Protein-based therapies hold promise for improving CNS disorder outcomes, but translation has been hampered by ineffective delivery. Biomaterial-based systems can improve the spatiotemporal control of local protein delivery to the CNS, although new bioengineering solutions are needed to address the limitations of currently available tools, particularly for loading and long-term stability of bioactive cargo as well as the extent of neuropil disruption that is caused by injection or implantation of these systems. Here, we address these issues by developing a trehalose-based complex coacervate platform that shows facile protein loading, tunable protein release, cytocompatibility, and a capacity to be dispersed within neural tissue with minimal induced FBR. Our findings demonstrate proof-of-principle that trehalose-based coacervates can be used to effectively deliver bioactive proteins locally to the CNS and have broad implications for: (i) using the trehalose-based coacervate platform as a versatile delivery vehicle and biotechnology tool, and (ii) applications of the coacervate-based therapies to treat CNS disorders.

Here we show that trehalose-based coacervates can load a variety of model proteins with a capacity to concentrate proteins directly from solutions while maintaining protein solubility and structural stability. There is growing interest in using coacervates

to address persistent and ubiquitous challenges facing the delivery, formulation, manufacture, and supply chain management of therapeutic biomolecules such as growth factors, antibodies, and viral vectors[60-62]. When applied to such therapeutics, coacervates formed using synthetic polypeptides or charged polysaccharides have already improved the capacity to prepare injectable, high concentration monoclonal antibody formulations[62], enhance the delivery of growth factors to stimulate angiogenesis[43], and confer biomolecule thermostability improvements to address cold chain challenges[61]. However, these existing coacervate technologies make use of polyelectrolytes that are not biodegradable and whose electrostatic interactions with biomolecules cannot be easily regulated, which poses problems for controlled protein release applications. The branched oligomer synthesis scheme used in the trehalose-based coacervate platform enables facile control of both trehalose content and charge density, and resulting oligomers are amenable to biodegradation by ester hydrolysis. Thus, by having control over oligomer-biomolecule charge interactions and the resorption of the coacervates, this trehalose-based system represents an important advance in coacervate technologies for drug delivery applications. The unique hydrogen bonding characteristics of trehalose confer protein stabilization properties superior to all other types of saccharides or small molecule excipients[30,63]. Multivalent incorporation of trehalose and the enhanced chain homogeneity provided by the step-growth Michael addition reaction mechanism used here to form the branched oligomers has the potential to further improve upon the stabilization capacity of both free trehalose and other previously developed coacervate systems[27]. Given the modular nature of trehalose-based coacervates, important next steps include dissecting the formulation space with different ionizable end-caps and multifunctional thiol molecules to tune coacervate properties such as electrostatic strength and branching structure.

While the focus of this study was on protein delivery to the CNS, this work opens exciting new research opportunities to extend the trehalose-based coacervate platform into a variety of other applications. For example, formulating coacervates with other molecular cargo such as small molecules or viral vectors could extend the utility of the co-

acervates as a general delivery tool. Mixing of differently loaded coacervates into a single bulk coacervate structure may enable precise temporal control over the release of multiple different drug cargos. Because of their substantial protein concentrating capacity and tunable properties, trehalose-based coacervates may also be a useful tool for protein purification processes where enrichment of specific proteins from dilute solutions could be achieved. Additionally, by being able to effectively concentrate biomolecules, trehalose-based coacervates could serve important new roles as catalytic sites for different chemical reactions. The unique capacity for trehalose-based coacervates to bind but not be internalized by cells *in vitro* could also support the use of coacervates as a practical bioprinting tool to grow cell sheets or organoids that could then be readily transferred or molded into distinct structures by leveraging the malleable, viscoelastic properties of the coacervates. However, outstanding questions remain as to why trehalose-based coacervates do not seem to be endocytosed by cells. It is possible that trehalose content, coacervate size, or induced protein corona interferes with the capacity of coacervates to cross the cell membrane. Future studies should focus on dissecting these mechanisms and determining whether precise tuning of charge imbalance or size can direct cellular uptake. While other coacervate systems have demonstrated an intracellular delivery capacity[57,58], the cellular uptake pathways used by coacervates are still poorly understood. Using the modular properties of trehalose-based coacervates to dissect this fundamental biology will be important if intracellular delivery of therapies, including nucleic acids or ribonucleoprotein complexes, is to be realized using coacervates.

Trehalose-based coacervates represent an important advance over shear thinning hydrogel systems for CNS neural parenchyma drug delivery. Previously, we have shown that hydrogel systems are useful tools for delivering growth factors to CNS injury lesion environments during the acute stage of injury[3,4], but when applied to healthy neural parenchyma, hydrogels disrupt large volumes of neural tissue at the precise site where bioactive protein is to be delivered[24]. Here we demonstrated that trehalose-based coacervates can be loaded with higher concentrations of therapeutic proteins and are readily dispersed into discrete volumes of neural parenchyma to deliver bioactive drugs

to neurons and glia without causing any of the extensive neural tissue displacement or inducing a substantial foreign body response, as seen with hydrogel injections. The proof-of-principle *in vivo* studies conducted in this work provide a strong foundation on which to explore numerous potential applications of the trehalose-based coacervate technology across CNS disorders in future studies. For example, trehalose-based coacervates will be useful for improving the delivery of chemoattracting factors for guiding stimulated axon regeneration after CNS injury, since we currently rely upon shear thinning hydrogels to deliver such factors[3,4]. Use of coacervates in CNS injury applications could also be extended to augment wound repair functions of astrocytes by delivering exogenous, or sequestering endogenous, growth cues that enhance astrocyte proliferation and migration[64]. Coacervates may also be useful for enhancing the bioactivity of delivered enzymes to effectively debride fibrotic lesions that pose an obstacle for axon regeneration[65] or afford precise remodeling of peri-neuronal nets to promote local neural circuit plasticity[66]. Furthermore, since trehalose-based coacervates bind to, but are not internalized by, neural cells, they have the potential to serve as new carriers for exogenous grafts. Then, their sustained delivery properties can be used to provide local growth cues, their protein sequestering properties can be used to concentrate endogenous supportive cues, and their viscoelastic and shear-thinning properties may be useful in providing protection to cells during *in vivo* infusion, while still enabling necessary dispersion of transplanted cells within the grafting site.

In conclusion, this work describes the development of new trehalose-based coacervates and proof-of-principle studies demonstrating their capacity to serve as effective controlled release protein delivery systems in the CNS. The results from this study lay the foundation for further investigation of coacervate-based delivery of proteins and other biomolecules in models of CNS disease to direct specific therapeutic outcomes.

Experimental procedures

Resource availability

Lead contact: Further information and requests for resources and materials should be directed to and will be fulfilled by the lead contact, Timothy M. O'Shea (toshea@bu.edu).

Materials

Trimethylolpropane tris(3-mercaptopropionate) (TMPTMP) (381489), 2-Carboxyethyl acrylate (55234), 2-(Dimethylamino)ethyl acrylate (330957), 3-Sulfopropyl acrylate potassium salt (251631), 2-(Acryloyloxy)ethyl trimethylammonium chloride solution (496146), 3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA (T0440), Sodium hydroxide 10M solution (72068), Hydrochloric acid solution (6N) (1430071000), 5,5′-Dithiobis(2-nitrobenzoic acid) (D218200), Lysozyme (L6876), Human IgG-FITC (F9636), Fluorescein isothiocyanate isomer I (F7250), Peroxidase from horseradish (77332), Fluorescein isothiocyanate–dextran (average molecular weights 10 kDa (FD10S) 70 kDa (FD70S), 150 kDa (46946)), Rhodamine B isothiocyanate–Dextran (R8881), Fluorescein o-acrylate (568856), and Albumin-fluorescein isothiocyanate conjugate (A9771) were purchased from Sigma-Aldrich. Lysozyme was FITC-labelled by reacting fluorescein isothiocyanate with lysozyme at a 1:10 molar ratio in 0.1 M borate buffer (pH 8.5) for 4 hours at 4°C. The reaction was then dialyzed against deionized (DI) H_2O for 48 hours at 4°C protected from light using a 3.5 kDa cutoff dialysis bag. The product was filtered, lyophilized, and stored at 4°C for use. Trehalose dihydrate (T0331), 2-(Dimethylamino)ethyl acrylate (A1235), 4-methoxyphenol (MEHQ) (M0123), N,N-Diisopropylethylamine (D1599), Ceric Ammonium Molybdate Solution (C1794), and 2,2,2-Trifluoroethyl acrylate (TFEA) (A1152) were purchased from TCI Chemicals. Celite 545 (AC349675000), 4A Molecular Sieves (AAL054540B), 2-Methyl-2-butanol (2M2B) (AAA183040F), Bovine Serum Albumin (BSA) (BP9706100), Agarose (IB70040), and activated alumina (Brockman I, basic) (6002042) were purchased from Thermo Scientific. Novozym 435 was received as a gift from Novozymes. Disposable

40g HP Silica Gold Cartridges were purchased from Teledyne Isco. All solvents (methanol, ethyl acetate, acetone, dimethyl sulfoxide (DMSO), N,N-Dimethylformamide (DMF)) were ACS grade and purchased from Fisher Scientific.

Synthesis of trehalose-based oligomers

Trehalose diacrylate was synthesized by reacting 8 molar excess of TFEA with lyophilized trehalose dihydrate in the presence of CALB at 50°C for 1 week. The reaction was solubilized in dry 2M2B with 2% DMSO and included 4A molecular sieves (4AMS) as well as MEHQ to prevent radical acrylate homopolymerization. The crude product was filtered to remove CALB and 4AMS and concentrated *in vacuo* using rotary evaporation. The product was precipitated into ethyl acetate, loaded onto Celite 545, and purified via flash chromatography using the ISCO CombiFlash system using a 40g silica cartridge and ethyl acetate and 80:20 methanol:deionized H_2O as the solvent mobile phases. Purified trehalose diacrylate was identified using thin layer chromatography (TLC) developed using CAM staining and collected fractions were dried *in vacuo* using rotary evaporation. A small quantity of MEHQ at approximately 40 mg per gram of reaction was included in the product to prevent radical acrylate homopolymerization during purification. The product was stored at 4°C under desiccant until use.

TMPTMP and all liquid acrylate end-caps were passed through basic alumina columns to remove the MEHQ inhibitor prior to use in oligomer synthesis reactions. Stoichiometrically defined amounts of TMPTMP, trehalose diacrylate, and mono-acrylate end-cap required for desired oligomer branching functionality (f_b) were solubilized at 10 wt% in DMF or 75/25 DMF/water. Typical reactions were prepared at 100-500 mg scale, catalyzed by 1/3 molar equivalent to thiols of DIEA and allowed to proceed for approximately 12 hours stirring at room temperature. Reaction progression was monitored using TLC that was developed using Ellman's stain to confirm the consumption of thiols in the reaction. Reactions were concentrated by rotary evaporation to remove DIEA and DMF. The crude oligomer product was solubilized in DI H_2O aided by appropriate acidification or alkalization achieved by adding one molar equivalent of HCl or NaOH to end-cap. Residual DMF and DIEA was removed via liquid-liquid extraction with ethyl acetate

and trace ethyl acetate was removed *in vacuo* by rotary evaporation. The resulting water-soluble oligomer was lyophilized and stored at 4°C until use.

Characterization of trehalose-based oligomers

^{1}H NMR spectra of trehalose diacrylate and synthesized oligomers were collected on an Agilent 500 MHz VNMRS spectrometer with a Varian ultra shielded magnet at concentrations of approximately 10 mg/mL in DMSO-d6. Hydrogen chemical shifts are expressed in parts per million (ppm) relative to the residual proton solvent resonance: DMSO-d6 δ2.50 or δ3.33. Number Molecular weight of branched oligomer was calculated using NMR. Fourier Transform Infrared Spectroscopy (FTIR) was performed using a Nicolet 4700 FTIR-ATR between the wavenumber region 4000-400 cm^{-1} (64 scans, 0.241 cm^{-1} resolution). Zeta potential measurement of constitutively charged oligomers solubilized at 10 mg/ml in water was performed using a Brookhaven NanoBrook Particle Size Analyzer. Solubility of oligomers was assessed using a series of pH adjusted buffers containing 10 mM HEPES, 10 mM MES, 10 mM sodium acetate, and 140 mM sodium chloride with pH values ranging from 3-8 in a 96-well plate with absorbance measured at 450 nm on the Molecular Devices SpectraMax i3X Microplate Detection Platform. pKa measurements of ionizable oligomers was performed using 2-(ptoluidino)-naphthalene-6-sulfonic acid (TNS) assay. For TNS assay, oligomers were solubilized in pH adjusted buffers at a concentration of 4 mg/ml prior to addition of TNS at a concentration of 2 μM. Sample fluorescence was measured in a 96-well plate using the same plate reader (excitation/emission 321/445 nm). A sigmoidal fit analysis was applied to the fluorescence data to determine the pKa value.

Formulation of trehalose-based coacervates

To form coacervates, oligomers were solubilized in DI water at 500 mg/ml and diluted into appropriate buffers at concentrations ranging from 1-100 mg/ml. Phosphate buffered saline with pH values ranging from 6-8 were used across coacervate characterization experiments. Polycation and polyanion oligomers were combined at charge equivalency or at defined molar ratios to form coacervates. Coacervates loaded with protein cargo were formulated with a desired loading ratio (LR, oligomer mass/protein

mass (mg/mg)) by combining the protein of interest prepared in a solution at 1-10 mg/ml in phosphate buffered saline with the polyionic oligomer of opposite charge (the appropriate oligomer was chosen based on the known isoelectric point for the protein). The oligomer with the same charge as the protein was then incorporated at the desired molar ratio to the protein-oligomer solution to generate coacervates.

Characterization of trehalose-based coacervates

Coacervate formulations were characterized by turbidity measurements that were performed in a 96-well plate with absorbance measured at 450 nm on a Molecular Devices SpectraMax i3X Microplate Detection Platform. Coacervate phase contrast images were acquired on Fisherbrand Inverted Microscope with Hayear camera attachment. Fluorescence imaging of FITC-labeled protein-loaded coacervates and fluorescein-labeled coacervates were obtained using an Olympus IX83 microscope. Rheological measurements of bulk coacervates were taken on a TA Instruments DHR-2 Rheometer, at 25°C with an 8 mm plate geometry. Coacervate nanodroplet diameter and polydispersity upon dilution and during disassembly *in vitro* were acquired using dynamic light scattering on a Brookhaven NanoBrook Particle Size Analyzer. Degradation of coacervates by hydrolysis was assessed by monitoring the emergence of a carboxylate (1550–1610 cm^{-1}) stretch signal by FTIR. Degradation and disassembly of coacervates was monitored by quantifying fluorescence using a Molecular Devices SpectraMax i3X Microplate Detection Platform.

Characterization of biomacromolecule encapsulation and release *in vitro* from coacervates

Coacervates were loaded with model biomacromolecules including FITC-dextrans, FITC-Lysozyme, FITC-BSA or FITC-IgG. Encapsulation efficiency of model biomacromolecules in coacervates was determined by centrifuging the formed coacervates into a pellet and then evaluating the depletion of protein from the resultant coacervate supernatant using microplate-based fluorescence detection (excitation/emission 488/520 nm). Concentrating factor was calculated by measuring the total volume of the resultant coacervate pellet and accounting for the total protein encapsulated based on

the above encapsulation efficiency measurements. For protein release, studies coacervates were incubated in 200 µL of PBS at 37°C with the incubation solution replaced daily. Protein concentrations in the recovered incubation solutions were read daily using microplate-based fluorescence detection. To benchmark protein release, eight-sample serially diluted standard curves were generated for each protein to convert the microplate measured fluorescence intensity into a protein concentration value. To model retention of coacervates and release of biomacromolecules in *in vitro* neural tissue-like environments, cargo loaded coacervates were injected into a 0.6 wt% agarose gel phantom brain[54]. Agarose phantoms were incubated in a PBS solution and the concentration of model biomacromolecules released from the agarose phantoms was characterized by microplate-based fluorescence detection. Bioactive protein recovery from coacervates was performed using HRP as a model enzyme. Active HRP in recovered incubation solutions was measured by developing with tetramethylbenzidine ELISA substrate for 5 minutes followed by adding 100 µL of 2N HCl solution to stop the enzymatic reaction. Absorbance was read at 450 nm on microplate reader and compared against a HRP solution standard. All plate reader assays were performed on a Molecular Devices SpectraMax i3X Microplate Detection Platform. Agarose gel images were obtained by placing gels with injected solution or coacervate on a coverslip and imaging using IX83 Olympus epifluorescence microscope at discrete timepoints.

In vitro cell culture assays and immunocytochemistry

Cytocompatibility of coacervates and individual oligomers *in vitro* with mouse neural progenitor cells (NPC) and differentiated astrocytes was assessed using Calcein AM cell viability assay. NPC were generated and cultured in neural expansion media supplement with EGF and FGF growth factors using standard methods described in detail previously by our team[67]. Astrocytes were derived by treating NPC with media containing 1% FBS for 2-4 days as we have done previously[55,67]. Cells were seeded on tissue culture treated 96-well plates at 50,000 cells per well and treated 24 or 48 hours later with coacervates suspended in media. Cell viability was assessed at 24 hours post-treatment by microplate-based fluorescence detection of Calcein AM (Cat# 354217, Corning) which was prepared at a molarity of 2µM. Calcein AM solution was incubated

with cells for 30min and read on a Molecular Devices SpectraMax i3X Microplate Detection Platform using an emission/excitation of 488/520 nm. Results were normalized with untreated control cells representing 100% viability and 80% methanol treated (dead) cells representing 0% viability. To assess cell attachment to bulk coacervates, individual wells of a non-treated polystyrene 96-well plate were coated with 2 mg/ml coacervate or individual oligomer solutions followed by addition of 50,000 cells per well. After 24 hours, non-adhered floating cells were transferred to a tissue culture treated 96-well plate. After an additional 24 hours of culture, both plates were treated with Calcein AM and cell numbers were evaluated by microplate fluorescence. All plate reader assays were performed on a Molecular Devices SpectraMax i3X Microplate Detection Platform. Cell interactions with coacervates were evaluated using fluorescein-labeled coacervates or coacervates loaded with FITC-BSA. NPC or astrocytes were seeded on gelatin coated glass coverslips and then treated with coacervates for 4 hours or 24 hours. Cell coverslips were fixed with 4% paraformaldehyde (prepared from 32% PFA Aqueous Solution (Cat# 15714, EMS)) with cell morphology and nucleus visualized using Acti-stain 555 phalloidin (1:2000, Cytoskeleton, PHDH1A) and DAPI (2ng/ml; Molecular probes) respectively. Coverslips were mounted onto microscope slides using Prolong Gold antifade reagent (Invitrogen, Cat# P36934) and imaged using an Olympus IX83 Widefield epifluorescence microscope.

Surgical procedures

All surgical procedures were approved by the BU IACUC (Protocol number: PROTO20200045) and conducted within a designated surgical facility. All procedures were performed on C57/BL6 female mice (Cat#000664, JAX) that were aged 8-12 weeks at the time of craniotomy. Mice were positioned into a rodent stereotaxic apparatus using ear bars (David Kopf, Tujunga, CA) and maintained under general anesthesia achieved through inhalation of isoflurane (1-3%) in oxygen-enriched air. Using the aid of a stereo microscope, a small rectangular shaped craniotomy was performed over the left coronal suture using a high-speed surgical drill. A small flap of bone encompassing sections of the frontal and parietal bone was removed to expose the surface of the brain prior to injection. Bulk coacervates (100% v/v), suspended coacervates (10% v/v

in PBS), BDA solution (0.4 wt%), NGF solution (2 mg/ml), or saline (1xPBS) were loaded into pulled borosilicate glass micropipettes (WPI #1B100-4) that were ground to a 35° beveled tip with 150–250 μm inner diameter after formulation with sterile-filtered components. Encapsulation of BDA in coacervates yielded a concentrating factor of ~1, ensuring the same concentration of BDA injected in solution and coacervate conditions. Glass micropipettes were mounted to the stereotaxic frame and high-pressure polyetheretherketone tubing and connectors were used to attach micropipettes to a 10 μL syringe (Hamilton, Reno, NV, #801 RN) that was mounted into a syringe pump (Pump 11 Elite, Harvard Apparatus). Coacervates or PBS containing either BDA (10 kDa—Thermofisher, #D1956) or recombinant human β-NGF (PeproTech, Cat# 450-01) were injected into the caudate putamen nucleus of the striatum at 0.15 μL/min using target coordinates relative to Bregma: +1.0 mm A/P, +2.5 mm L/M and −3.0 mm D/V. A total volume of 1 μL was used for all conditions. Once the complete volume of coacervate or solution had been injected the micropipette was allowed to dwell in the brain at the injection site for an additional 4 minutes before being slowly removed from the brain incrementally over a 2-min period. After injection, the surgical incision site was sutured closed with polyethylene sutures and the animals were allowed to recover. To benchmark results using coacervates with a bulk biomaterial, we used injections of 5 wt% methyl cellulose (MC) (Methocel A15C, [MW = 304 kDa; 27.5–31.5% substitution], Sigma #64625) hydrogels loaded with BDA as a control group in these studies.

Transcardial perfusion and immunohistochemistry

At 24 hours or 7 days after striatal injections, mice underwent terminal anesthesia by overdose of isoflurane and were then perfused transcardially with heparinized saline and 4% paraformaldehyde (PFA) using a peristaltic pump at a rate of 7 mL/min. Approximately, 10 mL of heparinized saline and 50 mL of 4% PFA were used per animal. Brains were dissected and post-fixed in 4% PFA for 6-8 hours followed by cryoprotection in 30% sucrose with 0.01% sodium azide in Tris-Buffered Saline (TBS) for at least 3 days at 4°C prior to cryosectioning. Coronal brain sections (40 μm thick) were cut using a cryostat (Leica CM1950 Cryostat). Tissue sections were stored in 96well plates im-

mersed with 1X TBS and 0.01% sodium azide solution at 4°C. For immunohistochemistry (IHC), tissue sections were stained using a free-floating staining protocol outlined in detail previously[55,67]. Following 1N HCl antigen retrieval and serial washes, the tissue sections were blocked and permeabilized using 1X TBS containing 5% Normal donkey serum (NDS, Jackson ImmunoResearch Laboratories) and 0.5% Triton x-100 for one hour. Tissue sections were then stained with primary antibodies overnight in 1X TBS containing 0.5% Triton x-100. The following primary antibodies were used in this study: anti-Rabbit NeuN (Abcam, ab177487, 1:1000); anti-Rat Gfap (Invitrogen, 13-0300, 1:1000); anti-Guinea pig Iba-1 (Synaptic Systems, 234 004, 1:500); anti-Rabbit P2ry12 (Ana Spec, AS-55043A, 1:800); anti-Goat Cd13 (R&D systems, AF2335, 1:500); anti-Rat Ly6b2 (BioRad, MCA771G, 1:200); anti-Goat ChAT (MilliporeSigma, AB144P, 1:500). Tissue sections were washed three times and incubated with appropriate secondary antibodies diluted at 1:250 in 1X TBS containing 0.5% Triton x-100 and 5% NDS for two hours. All secondary antibodies were affinity purified whole IgG(H + L) purchased from Jackson ImmunoResearch Laboratories, with donkey host and target specified by the primary antibody. BDA was visualized using streptavidin-HRP plus Tyr-Cy3 (PerkinElmer). Cell nuclei were counter stained with 4',6'-diamidino-2-phenylindole dihydrochloride (DAPI; 2 ng/ml; Molecular Probes) prior to mounting onto glass slides and then cover slipped with ProLong Gold (Invitrogen, Cat# P36934) anti-fade reagent. Stained sections were imaged using epifluorescence and deconvolution epifluorescence microscopy on an Olympus IX83 microscope.

Quantitative analysis of immunohistochemistry

Immunohistochemical staining intensity quantification for the various antibody markers or BDA was performed on tiled images prepared on the Olympus IX83 epifluorescence microscope that were taken at a standardized exposure time across groups and using the raw/uncorrected intensity settings. Quantification of total antibody staining or BDA accumulated into tissue was performed using NIH Image J (1.51) software and the Radial Profile Angle plugin as we have done before[24]. Total values for IHC stainings or detected BDA were determined by taking the integral (area under the curve) of the radial intensity profile. Bioactive NGF delivery was assessed by characterizing the relative

change in size of ChAT- and NeuN-positive cholinergic neurons and ChAT-positive neuropil on the ipsilateral striatum treated with NGF solution or coacervate compared to the contralateral striatum using the analyze particles function in NIH Image J (1.51) as done previously[24].

Statistical analysis

Statistical evaluations were conducted by one-way or 2way ANOVA with post hoc independent pairwise analysis via Tukey's or Sidak's multiple comparisons test where appropriate using Prism 10 (GraphPad Software Inc, San Diego, CA). Across all statistical tests, significance was defined as p-value <0.05. All graphs show mean values plus or minus standard error of the means (S.E.M.) as well as individual values overlaid as dot plots.

Data availability statement

All data generated for this study are included in the main and supplementary figures. For all quantitative figures, the results of statistical tests are provided with the paper. Files of source data of individual values and other data that support the findings of this study are available on reasonable request from the corresponding author.

Acknowledgements

This research is supported by the Biomedical Engineering Core Facilities at Boston University. A special thanks to Xin Brown and the Biointerface Technologies (BIT) core, as well as the Micro and Nano Imaging (MNI) core at BU. This research was also supported by the BU Chemistry Department Chemical Instrumentation Center (CIC) and staff. We are grateful to the National Science Foundation for the purchase of the NMR (CHE0619339) used in this work. This work was supported by internal Boston University start-up funds (T.M.O) and the Wings for Life Spinal Cord Research Foundation (T.M.O).

Conflict of Interest

The authors declare no conflict of interest.

References

1 Thorne, R. G. & Frey, W. H. Delivery of Neurotrophic Factors to the Central Nervous System. *Clinical Pharmacokinetics* **40**, 907-946 (2001).

2 Nance, E., Pun, S. H., Saigal, R. & Sellers, D. L. Drug delivery to the central nervous system. *Nature Reviews Materials* **7**, 314-331 (2022).

3 Anderson, M. A. *et al.* Astrocyte scar formation aids central nervous system axon regeneration. *Nature* **532**, 195 (2016).

4 Anderson, M. A. *et al.* Required growth facilitators propel axon regeneration across complete spinal cord injury. *Nature* **561**, 396-400 (2018).

5 Sofroniew, M. V., Howe, C. L. & Mobley, W. C. Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair. *Annu Rev Neurosci* **24**, 1217-1281 (2001).

6 Kobayashi, T. *et al.* Intracerebral infusion of glial cell line-derived neurotrophic factor promotes striatal neurogenesis after stroke in adult rats. *Stroke* **37**, 2361-2367 (2006).

7 Obermeyer, J. M. *et al.* Local Delivery of Brain-Derived Neurotrophic Factor Enables Behavioral Recovery and Tissue Repair in Stroke-Injured Rats. *Tissue Engineering Part A* **25**, 1175-1187 (2019).

8 Kang, S. S. *et al.* Endogenous CNTF mediates stroke-induced adult CNS neurogenesis in mice. *Neurobiology of disease* **49**, 68-78 (2013).

9 Houlton, J., Abumaria, N., Hinkley, S. F. R. & Clarkson, A. N. Therapeutic Potential of Neurotrophins for Repair After Brain Injury: A Helping Hand From Biomaterials. *Front Neurosci* **13** (2019).

10 Squair, J. W. *et al.* Recovery of walking after paralysis by regenerating characterized neurons to their natural target region. *Science (New York, N.Y.)* **381**, 1338-1345 (2023).

11 Eslamboli, A. *et al.* Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **25**, 769-777 (2005).

12 Tuszynski, M. H. Intraparenchymal NGF infusions rescue degenerating cholinergic neurons. *Cell Transplant* **9**, 629-636 (2000).

13 Whone, A. *et al.* Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. *Brain* **142**, 512-525 (2019).

14 García-Alías, G., Barkhuysen, S., Buckle, M. & Fawcett, J. W. Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. *Nature Neuroscience* **12**, 1145-1151 (2009).

15 Cafferty, W. B. J. *et al.* Chondroitinase ABC-Mediated Plasticity of Spinal Sensory Function. *The Journal of Neuroscience* **28**, 11998-12009 (2008).

16 Zurn, A. D., Widmer, H. R. & Aebischer, P. Sustained delivery of GDNF: towards a treatment for Parkinson’s disease. *Brain Research Reviews* **36**, 222-229 (2001).

17 Thomsen, G. M. *et al.* Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1(G93A) ALS rat but has adverse side effects. *Gene Ther* **24**, 245-252 (2017).

18 Arvidsson, A. *et al.* Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. *Neurobiology of Disease* **14**, 542-556 (2003).
19 Luz, M., Mohr, E. & Fibiger, H. C. GDNF-induced cerebellar toxicity: A brief review. *NeuroToxicology* **52**, 46-56 (2016).
20 Chan, S. J. *et al.* Endogenous regeneration: Engineering growth factors for stroke. *Neurochemistry International* **107**, 57-65 (2017).
21 Kearney, C. J. & Mooney, D. J. Macroscale delivery systems for molecular and cellular payloads. *Nature Materials* **12**, 1004 (2013).
22 Cook, D. J. *et al.* Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke. *Journal of Cerebral Blood Flow & Metabolism* **37**, 1030-1045 (2016).
23 Hunt, C. P. J. *et al.* Tissue Programmed Hydrogels Functionalized with GDNF Improve Human Neural Grafts in Parkinson's Disease. *Advanced Functional Materials* **n/a**, 2105301 (2021).
24 O'Shea, T. M. *et al.* Foreign body responses in central nervous system mimic natural wound responses and alter biomaterial functions. *Nature Communications* **11** (2020).
25 Lee, J. *et al.* Glucose-Responsive Trehalose Hydrogel for Insulin Stabilization and Delivery. *Macromolecular Bioscience* **18**, 1700372 (2018).
26 Lee, J. *et al.* Trehalose Glycopolymers as Excipients for Protein Stabilization. *Biomacromolecules* **14**, 2561-2569 (2013).
27 O'Shea, T. M., Webber, M. J., Aimetti, A. A. & Langer, R. Covalent Incorporation of Trehalose within Hydrogels for Enhanced Long-Term Functional Stability and Controlled Release of Biomacromolecules. *Advanced Healthcare Materials* **4**, 1802-1812 (2015).
28 Vinciguerra, D., Gelb, M. B. & Maynard, H. D. Synthesis and Application of Trehalose Materials. *JACS Au* **2**, 1561-1587 (2022).
29 Crowe, J. H. & Crowe, L. M. Preservation of mammalian cells-learning nature's tricks. *Nat Biotechnol* **18**, 145-146 (2000).
30 Jain, N. K. & Roy, I. Effect of trehalose on protein structure. *Protein Sci* **18**, 24-36 (2009).
31 Buchanan, S. S. *et al.* Cryopreservation of stem cells using trehalose: evaluation of the method using a human hematopoietic cell line. *Stem Cells Dev* **13**, 295-305 (2004).
32 DuBois, E. M., Adewumi, H. O., O'Connor, P. R., Labovitz, J. E. & O'Shea, T. M. Trehalose-Guanosine Glycopolymer Hydrogels Direct Adaptive Glia Responses in CNS Injury. *Advanced Materials* **n/a**, 2211774 (2023).
33 Mitchell, M. J. *et al.* Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery* **20**, 101-124 (2021).
34 Nance, E. A. *et al.* A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain Tissue. *Sci Transl Med* **4**, 149ra119-149ra119 (2012).
35 van de Weert, M., Hennink, W. E. & Jiskoot, W. Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles. *Pharmaceutical Research* **17**, 1159-1167 (2000).

36 Schwendeman, S. P., Shah, R. B., Bailey, B. A. & Schwendeman, A. S. Injectable controlled release depots for large molecules. *Journal of Controlled Release* **190**, 240-253 (2014).
37 Astoricchio, E., Alfano, C., Rajendran, L., Temussi, P. A. & Pastore, A. The Wide World of Coacervates: From the Sea to Neurodegeneration. *Trends in Biochemical Sciences* **45**, 706-717 (2020).
38 Johnson, N. R. & Wang, Y. Coacervate delivery systems for proteins and small molecule drugs. *Expert Opin Drug Deliv* **11**, 1829-1832 (2014).
39 Lindhoud, S. & Claessens, M. M. A. E. Accumulation of small protein molecules in a macroscopic complex coacervate. *Soft Matter* **12**, 408-413 (2016).
40 Zervoudis, N. A. & Obermeyer, A. C. The effects of protein charge patterning on complex coacervation. *Soft Matter* **17**, 6637-6645 (2021).
41 Black, K. A. *et al.* Protein Encapsulation via Polypeptide Complex Coacervation. *ACS Macro Letters* **3**, 1088-1091 (2014).
42 Davis, Bradley W. *et al.* Colocalization and Sequential Enzyme Activity in Aqueous Biphasic Systems: Experiments and Modeling. *Biophys J* **109**, 2182-2194 (2015).
43 Chu, H., Gao, J., Chen, C.-W., Huard, J. & Wang, Y. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis. *Proceedings of the National Academy of Sciences* **108**, 13444-13449 (2011).
44 Sen, S. & Puskas, J. E. Green Polymer Chemistry: Enzyme Catalysis for Polymer Functionalization. *Molecules* **20**, 9358-9379 (2015).
45 Perin, G. B. & Felisberti, M. I. Enzymatic synthesis and structural characterization of methacryloyl-D-fructose- and methacryloyl-D-glucose-based monomers and poly(methacryloyl-D-fructose)-based hydrogels. *Journal of Chemical Technology & Biotechnology* **93**, 1694-1704 (2018).
46 Chen, H. & Kong, J. Hyperbranched polymers from A2 + B3 strategy: recent advances in description and control of fine topology. *Polymer Chemistry* **7**, 3643-3663 (2016).
47 Unal, S. & Long, T. E. Highly Branched Poly(ether ester)s via Cyclization-Free Melt Condensation of A2 Oligomers and B3 Monomers. *Macromolecules* **39**, 2788-2793 (2006).
48 Sing, C. E. & Perry, S. L. Recent progress in the science of complex coacervation. *Soft Matter* **16**, 2885-2914 (2020).
49 Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. *Journal of Controlled Release* **114**, 100-109 (2006).
50 Jörgensen, A. M., Wibel, R. & Bernkop-Schnürch, A. Biodegradable Cationic and Ionizable Cationic Lipids: A Roadmap for Safer Pharmaceutical Excipients. *Small* **n/a**, 2206968 (2023).
51 Kamiya, N. & Klibanov, A. M. Controling the rate of protein release from polyelectrolyte complexes. *Biotechnology and Bioengineering* **82**, 590-594 (2003).
52 Zhang, C. *et al.* Strategies to enhance the distribution of nanotherapeutics in the brain. *Journal of Controlled Release* **267**, 232-239 (2017).

53 Wolak, D. J. & Thorne, R. G. Diffusion of Macromolecules in the Brain: Implications for Drug Delivery. *Mol Pharm* **10**, 1492-1504 (2013).
54 Chen, Z. J. *et al.* A realistic brain tissue phantom for intraparenchymal infusion studies. *J Neurosurg* **101**, 314-322 (2004).
55 Adewumi, H. O., Berniac, G. I., McCarthy, E. A. & O'Shea, T. M. Ischemic and hemorrhagic stroke lesion environments differentially alter the glia repair potential of neural progenitor cell and immature astrocyte grafts. *bioRxiv*, 2023.2008.2014.553293 (2023).
56 Zhang, Q., Phillips, H. R., Purchel, A., Hexum, J. K. & Reineke, T. M. Sustainable and Degradable Epoxy Resins from Trehalose, Cyclodextrin, and Soybean Oil Yield Tunable Mechanical Performance and Cell Adhesion. *ACS Sustainable Chemistry & Engineering* **6**, 14967-14978 (2018).
57 Sun, Y. *et al.* Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics. *Nature Chemistry* **14**, 274-283 (2022).
58 Iwata, T. *et al.* Liquid Droplet Formation and Facile Cytosolic Translocation of IgG in the Presence of Attenuated Cationic Amphiphilic Lytic Peptides. *Angewandte Chemie International Edition* **60**, 19804-19812 (2021).
59 Tabernero, A., Velasco, A., Granda, B., Lavado, E. M. & Medina, J. M. Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. *J Biol Chem* **277**, 4240-4246 (2002).
60 Jiskoot, W., Hawe, A., Menzen, T., Volkin, D. B. & Crommelin, D. J. A. Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis? *Journal of Pharmaceutical Sciences* **111**, 861-867 (2022).
61 Mi, X. *et al.* Thermostabilization of viruses via complex coacervation. *Biomater Sci* **8**, 7082-7092 (2020).
62 Bramham, J. E., Davies, S. A., Podmore, A. & Golovanov, A. P. Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation. *MAbs* **13**, 1940666 (2021).
63 Colaço, C., Sen, S., Thangavelu, M., Pinder, S. & Roser, B. Extraordinary Stability of Enzymes Dried in Trehalose: Simplified Molecular Biology. *Bio/Technology* **10**, 1007-1011 (1992).
64 O'Shea, T. M. *et al.* Border-forming wound repair astrocytes. *bioRxiv*, 2023.2008.2025.554857 (2023).
65 Zukor, K. *et al.* Short hairpin RNA against PTEN enhances regenerative growth of corticospinal tract axons after spinal cord injury. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **33**, 15350-15361 (2013).
66 Sorg, B. A. *et al.* Casting a Wide Net: Role of Perineuronal Nets in Neural Plasticity. *The Journal of Neuroscience* **36**, 11459-11468 (2016).
67 O'Shea, T. M. *et al.* Lesion environments direct transplanted neural progenitors towards a wound repair astroglial phenotype in mice. *Nature Communications* **13**, 5702 (2022).



Figure 1. Synthesis and characterization of trehalose-based oligomers.
A) Synthesis scheme for enzymatically catalyzed acylation reaction to prepare trehalose diacrylate and corresponding ^{1}H-NMR with characteristic peaks and associated integrations labeled.
B) Synthesis scheme for base-catalyzed A2+B3+AR thiol-ene Michael addition reactions to form trehalose-based oligomers. A: [2-(Acryloyloxy)ethyl] trimethylammonium chloride, S: 3-Sulfopropyl acrylate, D: 2-(Dimethylamino)ethyl acrylate, C: 2-Carboxyethyl acrylate.

C) TLC with Ellman's and CAM stains indicating progression of thiol-ene reactions after addition of each monomer.
D) ^{1}H-NMR of oligomers of the same branching functionality (f_b) with each of 4 end-caps with characteristic peaks highlighted.
E) FTIR of oligomers at 3 different f_b prepared with S end-cap with characteristic IR stretches of select chemical bonds highlighted.
F) Zeta potential measurements of constitutively positive bA oligomers at 3 different f_b and a constitutively negative bS oligomer. Graph shows mean ± SEM with n=6 cycles per group.



Figure 2. Solubility and coacervate formation of trehalose-based oligomers.
A) Solubility of oligomers (10 mg/ml) under increasing NaCl concentrations determined by spectrophotometric turbidity measurements.
B) pH dependent changes in solubility of ionizable oligomers (10 mg/ml).
C) Photographic images demonstrating the formation of coacervates from mixing of soluble oligomers by liquid-liquid phase separation.
D) Solubility of branching functionality (f_b) = 2.00 oligomers (10 mg/ml) and all combinations of end-caps at 1:1 molar ratios in isotonic phosphate buffer (pH 6). Not significant (ns) and *** $P < 0.0001$, one-way ANOVA with Tukey's multiple comparison test.
E) Pseudo-colored phase contrast images of coacervates formed from each combination of polycationic and polyanionic oligomers at f_b = 2.00. Oligomers are abbreviated by end-cap.
F) Pseudo-colored phase contrast images of soluble oligomers and same-charged combinations of oligomers at f_b = 2.00. Oligomers are abbreviated by end-cap.
(A, B) Threshold Abs450 = 0.5 set at point of visible turbidity.
All graphs show mean ± SEM with n=3-6.



Figure 3. Effect of formulation factors on complex coacervate derivation with bC2.00 and bD2.00 oligomers.

A) & B) Turbidity and corresponding phase contrast images for coacervates formed at oligomer concentrations ranging from 0.5-50 mg/ml in 20 mM phosphate buffer + 130 mM NaCl at pH 6 and 1:1 molar ratio.

C) & D) Turbidity and corresponding phase contrast images for coacervates formed at C:D molar ratios ranging from 16:1 to 1:16 at 10 mg/ml in 20 mM phosphate buffer + 130 mM NaCl. C:D denotes molar ratio of bC2.00 to bD2.00.

E) & F) Turbidity and corresponding phase contrast images of coacervates at NaCl concentrations ranging from 0-500 mM at 10 mg/ml 20 mM phosphate buffer at pH 6 and 1:1 molar ratio measured by absorbance at 450 nm.
G) & H) Turbidity and corresponding phase contrast images of coacervates at different pH values ranging from pH 6-8 at 10 mg/ml in 20 mM phosphate buffer + 130 mM NaCl at 1:1 molar ratio.
I) Phase contrast images of coacervates: upon formation at 25 mg/ml and 1:1 molar ratio in isotonic PBS at pH 7.4; after being left to coalesce for 15 minutes; and after being resuspended following a 2-fold dilution.
J) Diameter of coacervates serially diluted from 1 mg/ml at 1:1 molar ratio in PBS as measured by DLS. Graph shows mean ± SEM with n=5.
(A, C, E, G) Graphs show mean ± SEM with n=3 & Threshold Abs450 = 0.5 set at point of visible turbidity.
(A, C) One sample t test below theoretical mean Abs450 = 0.5. ** $P < 0.01$, **** $P < 0.0001$.



Figure 4. Protein-loading in trehalose-based coacervates.
A) Fluorescence images of coacervates loaded with FITC-Lyz at loading ratios (LR) = 25, 50, 100 in PBS. FITC-Lyz concentration = 1 mg/ml.
B) Size analysis of coacervates at LR = 25, 50, 100. Box & whiskers, min to max, midline denotes median.
C) Encapsulation efficiency and concentrating factor of FITC-Lyz with increasing concentration of total oligomer in PBS. Constant LR = 10.
D) Encapsulation efficiency and concentrating factor of FITC-Lyz with increasing LR in PBS. Constant protein concentration = 3.6 mg/ml.
E) Encapsulation efficiency and concentrating factor of 4 different model protein solutions. FITC-Lyz, FITC-BSA, FITC-IgG coacervates formed with LR = 50, C:D = 1:1 in PBS. NGF coacervates formed with LR = 100, C:D = 1.25:1 in PBS; measured by ELISA.
F) Encapsulation efficiency of FITC-Lyz at constant LR = 10 and oligomer concentration = 10 mg/ml at C:D ratios from 0:1 to 1:0. All groups compared to 1:1.
G) Encapsulation efficiency of FITC-BSA at constant LR = 10 and oligomer concentration = 10 mg/ml at C:D ratios from 0:1 to 1:0. All groups compared to 1:1.
H) Encapsulation efficiency of FITC-Lyz and FITC-BSA constant LR = 50 and oligomer concentration = 50 mg/ml with slight C:D molar excesses.
(C-H) Graphs show mean ± SEM with n=2-3.
All statistical tests are ordinary one-way ANOVA with Tukey's multiple comparisons test. **** $P < 0.0001$.



Figure 5. Temporally controlled bioactive protein release from coacervates.
A) Percent mass released from bulk fluorescein-coacervates of different mass over 10 days.
B) Diameter of particles detected in supernatant retrieved from incubated coacervates over 1 week at 37°C measured by DLS. Graph shows mean ± SEM with n=5 cycles.
C) FTIR of coacervate material before and after release showing minimal change in the carboxylate stretch region.
D) FITC-Lyz released from bulk coacervate at different LRs. LR 25 = 17.5 mg oligomer, LR 50 = 35 mg oligomer, LR 100 = 70 mg oligomer.
E) FITC-Lyz released from bulk coacervate loaded with FITC-Lyz at different C:D ratios. LR = 50, oligomer mass = 40 mg.

F) FITC-BSA released from bulk coacervate loaded with FITC-BSA at different C:D ratios. LR = 50, oligomer mass = 40 mg.
G) Fluorescence images of rhodamine-dextran solution (top) and rhodamine-dextran loaded fluorescein-coacervates (middle, bottom) diffusing through 0.6 wt% agarose gel over 24 hours.
H) Retention of FITC-dextrans in coacervate or solution at MW 10kDa, 70 kDa, 150 kDa in 0.6 wt% agarose gel.
I) Retention profile of FITC-Lyz in coacervate or solution in 0.6 wt% agarose gel.
J) Horseradish peroxidase (HRP) bioactivity measured over 4 days at 37°C in coacervate or solution. Measured with TMB substrate and absorbance at 450 nm.
K) HRP bioactivity measured after 1-hour incubations in coacervate or solution at different temperatures. Measured with TMB substrate and absorbance at 450 nm.
(A, D-F, H-K) Graphs shows mean ± SEM with n=3.
(H-K) 2way ANOVA with Sidak's multiple comparisons test. Not significant (ns), *** $P < 0.001$, **** $P < 0.0001$.



Figure 6. Coacervates are cytocompatible *in vitro*.

A) Viability of neural progenitor cells (NPC) with coacervates and individual oligomers all at 1 mg/ml; measured by Calcein AM assay.
B) NPC cell attachment to coacervate and individual oligomers (2 mg/ml) compared to untreated (polystyrene) and benchmarked against tissue culture treated plastic, measured by Calcein AM assay. Comparisons made to polystyrene control.
C) Image of NPC treated with fluorescein-coacervates (1 mg/ml) for 24 hours. Stained with DAPI and phalloidin.
D) Viability of astrocytes with coacervates and individual oligomers all at 1 mg/ml; measured by Calcein AM assay.
E) Astrocyte cell attachment to coacervate and individual oligomers (2 mg/ml) compared to untreated (polystyrene) and benchmarked against tissue culture treated plastic, measured by Calcein AM assay. Comparison made to polystyrene control.
F) Images of astrocytes treated with fluorescein-coacervates (1 mg/ml) for 24 hours. Stained with DAPI and phalloidin.
G) Images of astrocytes treated with fluorescein-coacervates (5 mg/ml), FITC-BSA solution (10 µg/ml), and FITC-BSA coacervates (10 µg/ml FITC-BSA, LR = 500) for 4 hours. Stained with DAPI and phalloidin.

All graphs show mean ± SEM with n=7-8 with ordinary one-way ANOVA with Tukey's multiple comparisons test. Not significant (ns), * $P < 0.05$, **** $P < 0.0001$.



Figure 7. BDA-loaded coacervates delivered to the healthy mouse striatum 7 days after injection. A) Survey images showing biotinylated dextran amine (BDA) dispersion through brain with BDA-loaded solution, suspended (10% v/v) and bulk (100% v/v) coacervate, and methyl cellulose (MC) gel injections into the striatum.

B) Detailed images showing BDA deposit at the injection site and proximity to nearby neurons with BDA-loaded solution, 10% v/v and 100% v/v coacervate, and methyl cellulose gel injections.

C) Cumulative percent BDA delivered to neural tissue over 1.5 mm radial distance from injection site.
D) Radial distance from injection at which 50% of total cumulative BDA is dispersed.
E) Radial intensity profile for BDA indicating the radial dispersion of BDA from striatal injection site.
F) Total BDA in ipsilateral striatum and cortex.
G) Images of reactive astrocyte response (Gfap) and neural cell (NeuN) displacement at injection site.
H) Radial intensity profile of Gfap-positive astrocytes evaluated from the striatal injection epicenter.
I) Radial distance from injection epicenter to the start of NeuN-positive neural tissue.
All graphs show mean ± SEM with n=4-5. Ordinary one-way ANOVA with Tukey's multiple comparisons test. Not significant (ns), ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.



Figure 8. Local delivery of NGF to ChAT+ neurons in mouse striatum using coacervates 7 days after injection.

A) Detailed images of choline acetyltransferase (ChAT)-positive neurons among neural tissue (NeuN) with nerve growth factor (NGF) coacervate delivery in ipsilateral and contralateral striatum.

B) Quantification of percent change in size of ChAT-positive neurons from ipsilateral to contralateral striatum with saline, NGF solution, and NGF coacervate injections. Ordinary one-way ANOVA with Tukey's multiple comparisons test.

C) Quantification of percent change in intensity of ChAT staining from ipsilateral to contralateral striatum with saline, NGF solution, and NGF coacervate injections. Ordinary one-way ANOVA with Tukey's multiple comparisons test.

D) Radial intensity of ChAT staining from injection site.

E) Radial intensity of ChAT staining from center of contralateral striatum.

F) Cumulative ChAT intensity radially from injection site. 2way ANOVA with Tukey's multiple comparisons test. Comparisons shown on graph are from final point and compared to saline.

G) Cumulative ChAT intensity radially from center of contralateral striatum. 2way ANOVA with Tukey's multiple comparisons test. Comparisons shown on graph are from final point and compared to saline.

(D, E) 2way ANOVA with Tukey's multiple comparisons test performed on every 50th pixel in radial angle profile – sections indicate where minimum P value is consistent. All comparisons made to saline.

All graphs show mean ± SEM with n=5-8. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.